Stay updated on Magrolimab in Hematological Malignancies Clinical Trial
Sign up to get notified when there's something new on the Magrolimab in Hematological Malignancies Clinical Trial page.

Latest updates to the Magrolimab in Hematological Malignancies Clinical Trial page
- CheckyesterdayChange DetectedA sitewide NIH banner announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe footer now displays an updated ClinicalTrials.gov site revision identifier.SummaryDifference0.2%

- Check22 days agoChange DetectedAccess to the study page now returns a 403 Forbidden error, replacing the expected study content. This indicates a permissions issue rather than an update to the study data or page features.SummaryDifference22%

- Check36 days agoChange DetectedThe page shows Revision: v3.7.0, replacing the previous Revision: v3.6.6. This indicates a software version update applied to the page.SummaryDifference0.0%

- Check50 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6. This signals a new release of the ClinicalTrials.gov interface/backend, and the visible study content remains unchanged.SummaryDifference0.0%

- Check57 days agoChange DetectedThe page now includes a line indicating 2017 U.S. NIH grant/contract funding in the study's information.SummaryDifference0.0%

Stay in the know with updates to Magrolimab in Hematological Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab in Hematological Malignancies Clinical Trial page.